40
Participants
Start Date
April 13, 2022
Primary Completion Date
February 5, 2024
Study Completion Date
February 29, 2024
Estradiol / Progesterone
Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
Sexual event
A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
CHU de Montpellier, Montpellier
Collaborators (2)
IBSA Institut Biochimique SA
INDUSTRY
Ferring Pharmaceuticals
INDUSTRY
University Hospital, Montpellier
OTHER